F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
Price : $35 *
At a glance
- Drugs Olorofim (Primary)
- Indications Aspergillosis
- Focus Adverse reactions
- Sponsors F2G
- 16 Sep 2016 Status changed from recruiting to completed.
- 08 Aug 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
- 08 Aug 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Sep 2016.